Early Detection. Healthy Life.
EarlyDiagnostics (EarlyDx) is building the foundational platform for human health by transforming cell-free DNA into Whole-Body Molecular Insights. Powered by MethylScan™, our proprietary epigenomic platform, a single blood draw enables early disease detection, patient risk stratification, precision medicine, and longitudinal health monitoring.
About
Big Data for Better Diagnosis
We have developed a blood test, CancerRadar, which is highly accurate and sensitive in detecting and locating cancer. In addition, we developed a One-Stop Shop bioinformatics solution, EarlyDx-Cloud, to help many diagnostic companies offer liquid biopsy tests for cancer detection, therapy selection, and treatment monitoring.
how it works
The Technology behind Cancer Detection
Discover our experimental and computational innovations.
MethylScan™
MethylScan™ is EarlyDiagnostics proprietary next-generation epigenomic platform for blood-based disease detection, enabling cancer screening, biomarker discovery, patient risk stratification, and minimal residual disease (MRD) monitoring across oncology and liver disease.
cfSNV
A novel computational tool to accurately call mutations directly from blood.
cfTrack
Non-invasive monitoring of cancer MRD, Recurrence, and Evolution.
EarlyDx-Cloud
A “One-Stop Shop” bioinformatics solution for liquid biopsy.
Publications
Our technologies are empowered by Innovation.
Our Team
Our Experts Are Waiting For You
We bring the right people together to challenge established thinking and drive transformation.
Latest News
Read the latest news and blog posts from EarlyDx.
July 2026
EarlyDiagnostics announced the publication of the clinical validation results of its proprietary MethylScan™ platform for hepatocellular carcinoma (HCC) surveillance in Hepatology Communications. The study, titled "Methylation Plus Alpha-Fetoprotein Blood Test for Early Detection of HCC in At-Risk Populations," demonstrated that MethylScan™ HCC achieved 73% sensitivity at 92% specificity for detecting early-stage HCC (within Milan criteria). [Hepatology Communications]
May 2026
EarlyDiagnostics (EarlyDx) announced that its proprietary MethylScan™ platform has been validated in a peer-reviewed study published in the Proceedings of the National Academy of Sciences (PNAS). The study demonstrated that MethylScan™ can detect multiple cancers, liver diseases, and organ abnormalities from a single blood sample.
[NBC News] [BusinessWire] [U.S. News & World Report]
April 2026
EarlyDx is exhibiting at AACR 2026. We welcome opportunities to discuss collaborations and strategic partnerships.